A major breakthrough in the understanding and future control of deadly cholera epidemics
In a report publishing October 17th, 2013 in PLOS Neglected Tropical Diseases, the international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) and its scientific research arm, Epicentre, present results of one of the first-ever, large-scale use of an oral cholera vaccine during a cholera outbreak — a major breakthrough in the understanding and future control of deadly cholera epidemics.
Using results from a mass vaccination campaign of more than 300,000 people conducted in Guinea last year, MSF and Epicentre show the feasibility of implementing a mass vaccination campaign with oral cholera at the onset of an outbreak, similar to the way reactive vaccination campaigns are conducted when diseases such as measles or meningitis are reported in an area.
Last year, MSF teams in Guinea noticed cases of cholera months ahead of the rainy season. These early cholera cases and other factors, including the lack of a cholera epidemic in Guinea for several years, and the ongoing cholera epidemic in neighboring Sierra Leone, were strong indications to MSF and the Ministry of Health that a major cholera epidemic was imminent.
Starting in April of last year the Guinean Ministry of Health and MSF administered 316,250 doses of vaccine during two vaccination rounds in the coastal districts of Boffa and Forecariah, Guinea over six weeks. All individuals older than 12 months were eligible for vaccination in both rounds. The vaccination campaign was well accepted by the local community and MSF achieved high coverage rates. The two doses vaccine coverage was 75.8% in Boffa and 75.9% in Forecariah, respectively. Almost all people surveyed after the campaign, 98.9 percent, reported that they would be vaccinated again in a future cholera campaign.
Oral cholera vaccine was added to the WHO recommendation for cholera treatment in 2010, but so far has not been commonly used as a public health tool for control of the disease. Concerns about its feasibility, timeliness and acceptability by population, as well as fear of diverting resources from other medical programs have discouraged the use of an oral cholera vaccine.
The Latest on: Oral Cholera Vaccine
- How New IBM Cloud Service Will Detect Bias in AI on September 20, 2018 at 12:55 am
Big Blue’s Trust and Transparency service also will help mitigate bias and show businesses how their AI systems reach their decisions. Artificial intelligence holds the promise for enterprises of bein... […]
- IBM launches system to detect unconscious bias in AI algorithms on September 19, 2018 at 4:51 am
This tool scans for signs of bias and recommends adjustments. The kit identifies the different factors an artificial intelligence (AI) system has used to reach a decision: for instance, determining wh... […]
- IBM Debuts Tools to Help Prevent Bias In Artificial Intelligence on September 18, 2018 at 9:01 pm
IBM wants to help companies mitigate the chances that their artificial intelligence technologies ... The technology industry is increasingly combating the problem of bias in machine learning systems, ... […]
- ‘Inequality wasn’t the intention, but inequality was the outcome’: Addressing bias in AI software on August 27, 2018 at 1:53 pm
Karandish, co-founder and CEO of Jane.ai, joined host Don Marsh along with implicit bias researcher Calvin Lai to discuss the crossover between artificial intelligence and unconscious ... we’re baking ... […]
- Study finds gender and skin-type bias in commercial artificial-intelligence systems on July 18, 2018 at 2:47 pm
Three commercially released facial-analysis programs from major technology companies demonstrate both skin-type and gender biases, according to new research. 21 February, 2018 Beyond trigger warnings ... […]
via Google News and Bing News